Skip to main content
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
3.200
+0.040 (1.27%)
At close: Dec 20, 2024, 4:00 PM
3.270
+0.070 (2.19%)
After-hours: Dec 20, 2024, 5:59 PM EST

Inhibikase Therapeutics Revenue

Inhibikase Therapeutics had revenue of $1.00 in the twelve months ending September 30, 2024, down -100.00% year-over-year. In the year 2023, Inhibikase Therapeutics had annual revenue of $260.50K with 111.03% growth.

Revenue (ttm)
$1.00
Revenue Growth
-100.00%
P/S Ratio
n/a
Revenue / Employee
$0
Employees
9
Market Cap
215.02M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023260.50K137.06K111.03%
Dec 31, 2022123.44K-2.98M-96.02%
Dec 31, 20213.10M2.40M343.92%
Dec 31, 2020698.47K-424.27K-37.79%
Dec 31, 20191.12M-2.92M-72.22%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
biote 193.06M
LifeMD 193.06M
Fulcrum Therapeutics 80.87M
Utah Medical Products 44.08M
Zentalis Pharmaceuticals 40.56M
Mersana Therapeutics 34.84M
Ocugen 4.70M
Precigen 3.96M
Revenue Rankings

IKT News

More News